Relevance of ctdnalit-20261011-zeng2026-protocol-pe-validation to "Which fragmentomics workflow detects tumour-derived plasma DNA under realistic low tumour fractions and fixed false-positive constraints?"
- Use case
- Select a plasma ctDNA fragmentomics detection workflow
- Assessed by
- Zeng et al. 2026 independent PE validation dataset: cancer vs healthy
- Relevance
- Proxy evidence
- Endpoint
- Cancer vs healthy ROC-AUC and sensitivity at 99% specificity (means over 10 fold models) for 5' end-motif, fragment ratio, insert size and nucleosome peak feature sets from cfMeDIP-seq reads, alone and combined with methylation: independent pe validation dataset
Compares several fragmentomic feature sets on the same plasma samples at a fixed 99% specificity, with an independent validation dataset. Proxy: the fragments are cfMeDIP-enriched (methylated) reads rather than whole-genome sequencing, no tumour-fraction stratum is reported, and the developer ran every arm.
Evidence
Source checking verifies the cited claim or transcription. It does not establish independent reproduction.
Evidence table
Inspect claims, sources and review details
Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.
One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.
42 evidence rows matching the loaded filters
| Property and statement | Original source and location | Review and provenance |
|---|---|---|
Citation locations2 values
| A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature Cancer, published online 2026-02-19; Europe PMC full-text JATS XML of PMC12948677 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Citation locations2 values
| Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Comparison group zeng2026-cfmedip-feature-sets Context-only references | A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature Cancer, published online 2026-02-19; Europe PMC full-text JATS XML of PMC12948677 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Comparison group zeng2026-cfmedip-feature-sets Context-only references | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Comparison title cfMeDIP-seq methylation and fragmentomic feature sets on the same samples (Zeng et al. 2026) Context-only references | A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature Cancer, published online 2026-02-19; Europe PMC full-text JATS XML of PMC12948677 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Comparison title cfMeDIP-seq methylation and fragmentomic feature sets on the same samples (Zeng et al. 2026) Context-only references | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Constraints3 values
| A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature Cancer, published online 2026-02-19; Europe PMC full-text JATS XML of PMC12948677 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Constraints3 values
| Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Endpoint Cancer vs healthy ROC-AUC and sensitivity at 99% specificity (means over 10 fold models) for 5' end-motif, fragment ratio, insert size and nucleosome peak feature sets from cfMeDIP-seq reads, alone and combined with methylation: independent pe validation dataset Context-only references | A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: Nature Cancer, published online 2026-02-19; Europe PMC full-text JATS XML of PMC12948677 | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
| Endpoint Cancer vs healthy ROC-AUC and sensitivity at 99% specificity (means over 10 fold models) for 5' end-motif, fragment ratio, insert size and nucleosome peak feature sets from cfMeDIP-seq reads, alone and combined with methylation: independent pe validation dataset Context-only references | Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file | not individually reviewed No individual claim review recorded Audit detailsField: Source artifact SHA-256: Hash scope: Hash scope not separately documented; inspect source record |
Sources and history
Release 2026-11-21-c8bea25e5abb · Record review: source checked
2 source records and release history
- A pan-cancer compendium of 1,294 plasma cell-free DNA methylomes and fragmentomes enabling multicancer detection · Original source · Nature Cancer, published online 2026-02-19; Europe PMC full-text JATS XML of PMC12948677
- Zeng et al. 2026, Source Data Fig. 4 (classifier AUC and sensitivity summaries) · Original source · 43018_2026_1116_MOESM6_ESM.xlsx (Source Data Fig. 4), publisher supplementary file
Technical metadata and extraction receipts
Stable ID: use-case-mapping-ctdna-lit-20261011-zeng2026-frag-pe-validation
- field
- links:assessed_by:ctdnalit-20261011-zeng2026-protocol-pe-validation
- value
- ctdnalit-20261011-zeng2026-protocol-pe-validation
- relevance
- proxy
- endpoint
- Cancer vs healthy ROC-AUC and sensitivity at 99% specificity (means over 10 fold models) for 5' end-motif, fragment ratio, insert size and nucleosome peak feature sets from cfMeDIP-seq reads, alone and combined with methylation: independent pe validation dataset
- rationale
- Compares several fragmentomic feature sets on the same plasma samples at a fixed 99% specificity, with an independent validation dataset. Proxy: the fragments are cfMeDIP-enriched (methylated) reads rather than whole-genome sequencing, no tumour-fraction stratum is reported, and the developer ran every arm.
- constraints
- Inspect every linked evaluation's source locator and preserved limitations before citing a result.; Do not combine this mapping's evaluations with any other protocol's results; assays, cohorts and validation designs differ.; Fold-model means are not sample-level confidence intervals; spreads are across 10 fold models.
- limitations
- Developer study: the authors produced the cfMeDIP-seq cohorts and built and ran every classifier.; Clinically diagnosed cancers, many metastatic or advanced, against healthy donors; not an intended-use screening population.; Values are summaries over the 10 cross-validation fold models; the fold-level spread is reported, not a confidence interval over samples.; Fragmentomic features are computed from cfMeDIP-enriched (methylated) fragments, not from whole-genome sequencing.; Spread of sensitivity values: Source Data columns are headed sd_sens99 and the sheets' text column prints 'Sensitivity=x ± y'; the Figure 4 legend says the error bars in panels b, d, f and h are s.e.; The 17 healthy controls from the HCC study used a different laboratory protocol; the authors say this lowered the AUC and sensitivity of every classifier that includes 5' end motifs.; LFS-previvor and LFS-survivor carriers without current cancer are labelled as cancer for sensitivity summaries.; Validation size is printed as 95 baseline samples in the Results and n = 140 in the Extended Data Fig. 9f legend.; No tumour-fraction stratification is reported for these classifiers.; The validation set has 17 healthy controls (Results P28 and P32), so a 99% specificity threshold allows no false positive among them (counts from the source; the resolution is Rewire arithmetic).
- citation locators
- source id: ctdnalit-20261011-zeng2026-source-article; locator: Results P28-P33; Fig. 4 legend; Methods P59-P62; source id: ctdnalit-20261011-zeng2026-source-source-data-fig4; locator: Sheets Fig.4a-Fig.4h
- source locator
- ctdnalit-20261011-zeng2026-source-article: Results P28-P33; Fig. 4 legend; Methods P59-P62; ctdnalit-20261011-zeng2026-source-source-data-fig4: Sheets Fig.4a-Fig.4h
- revision
- 1
- reason
- Add the same-sample cfMeDIP-seq methylation and fragmentomic classifier comparison of Zeng et al. 2026 (Nature Cancer), retrieved 2026-10-11. Independently reviewed in docs/reviews/use-cases/plasma-ctdna-use-cases-2026-10-12.md.
- comparison group
- zeng2026-cfmedip-feature-sets
- comparison title
- cfMeDIP-seq methylation and fragmentomic feature sets on the same samples (Zeng et al. 2026)
- headline metric
- auroc
- stratum label
- Independent PE validation dataset
- stratum order
- 2
- excluded evaluations
- id: ctdnalit-20261011-zeng2026-eval-pe-validation-end-motifs; reason: Includes 5' end motifs; the authors attribute motif-containing classifiers' validation scores to a laboratory-protocol difference in the HCC-study healthy controls (Results P32), so the values reflect that batch effect, not the classifier.; id: ctdnalit-20261011-zeng2026-eval-pe-validation-motif-methylation-1pct; reason: Includes 5' end motifs; the authors attribute motif-containing classifiers' validation scores to a laboratory-protocol difference in the HCC-study healthy controls (Results P32), so the values reflect that batch effect, not the classifier.; id: ctdnalit-20261011-zeng2026-eval-pe-validation-motif-methylation-ratios-1pct; reason: Includes 5' end motifs; the authors attribute motif-containing classifiers' validation scores to a laboratory-protocol difference in the HCC-study healthy controls (Results P32), so the values reflect that batch effect, not the classifier.; id: ctdnalit-20261011-zeng2026-eval-pe-validation-all-features-1pct; reason: Includes 5' end motifs; the authors attribute motif-containing classifiers' validation scores to a laboratory-protocol difference in the HCC-study healthy controls (Results P32), so the values reflect that batch effect, not the classifier.; id: ctdnalit-20261011-zeng2026-eval-pe-validation-all-features-5pct; reason: Includes 5' end motifs; the authors attribute motif-containing classifiers' validation scores to a laboratory-protocol difference in the HCC-study healthy controls (Results P32), so the values reflect that batch effect, not the classifier.
- review
- method: source-hash-verification; independent-cell-check; scope-review; method note: Re-downloaded the pinned sources and matched their SHA-256. Opened the cell named by every result's source_locator on the reviewed evaluations with a script written for this review (the extractor's and earlier reviewers' scripts were not run), compared it with printed_value, numeric_value and any interval, and checked the row labels the locator quotes. Re-checked every disputed result and excluded evaluation against the source, and the endpoint, relevance grade and limitations against the use case.; reviewer: claude; reviewer note: Separate Claude review agent, independent of the extractors, of the agents that drafted these claims and of their earlier reviewers; no human review claimed; reviewed at: 2026-10-14T13:30:00Z; note: Re-review after the judgement was withheld in releases as changed evidence (issue #126). Nothing it rests on had changed: the build compared an evidence hash computed over the whole store with one computed over public records, and this judgement's evaluations have disputed results, which only the store holds. Every value matches its source; every dispute is supported; no text, value or verdict changes. Earlier review 2026-10-12. See docs/reviews/use-cases/plasma-ctdna-withheld-judgements-2026-10-14.md.
- reviewed evaluations
- ctdnalit-20261011-zeng2026-eval-pe-validation-fragment-ratio; ctdnalit-20261011-zeng2026-eval-pe-validation-insert-size; ctdnalit-20261011-zeng2026-eval-pe-validation-methylation; ctdnalit-20261011-zeng2026-eval-pe-validation-nucleosome-peak; ctdnalit-20261011-zeng2026-eval-pe-validation-ratios-methylation-1pct
- pins
- record id: ctdnalit-20261011-zeng2026-eval-pe-validation-fragment-ratio; fields: status; links; attributes.origin; attributes.comparison; sha256: 9f0aa42a8db785d52ce3b7ba0cba158bf19049d6ddd408cdf915d653f1b81b19; record id: ctdnalit-20261011-zeng2026-eval-pe-validation-insert-size; fields: status; links; attributes.origin; attributes.comparison; sha256: 33b8cd49220d2601bb4026858cbb6e477c2860614df31bfa72efcaf6be9977c9; record id: ctdnalit-20261011-zeng2026-eval-pe-validation-methylation; fields: status; links; attributes.origin; attributes.comparison; sha256: f784821abe2575f73ce319d31f976c634aa3add495902a4f216107360a8e1f1e; record id: ctdnalit-20261011-zeng2026-eval-pe-validation-nucleosome-peak; fields: status; links; attributes.origin; attributes.comparison; sha256: c82ac4ad447d7bcd2ac5e46ffe1ec8be1d6e3052a549acc9b441c3d78263217c; record id: ctdnalit-20261011-zeng2026-eval-pe-validation-ratios-methylation-1pct; fields: status; links; attributes.origin; attributes.comparison; sha256: 945f3e5f1992c8a095438bbec758789b0f0cf327f890333670518f6aa6887ca7; record id: ctdnalit-20261011-zeng2026-protocol-pe-validation; fields: status; name; description; facets; source_ids; links; attributes; sha256: 4810119b20f2d5e5ffee27535ec5fae5f5c8908273c603cda51d03bc7e0f720e; record id: ctdnalit-20261011-zeng2026-result-pe-validation-fragment-ratio-auroc; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 43ef7f97551527d5264281de144e994cb9850624a953fc3a1576b53b966de8bc; record id: ctdnalit-20261011-zeng2026-result-pe-validation-fragment-ratio-sensitivity-99spec; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: da2c50013c9551513ff3491af6940905f8923d2c4aca730cbbb165a020d841e5; record id: ctdnalit-20261011-zeng2026-result-pe-validation-insert-size-auroc; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 21093d8b1dd18426df1a9a765d46754835c9366c01271896204cd8fbc264ab9e; record id: ctdnalit-20261011-zeng2026-result-pe-validation-insert-size-sensitivity-99spec; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 1cc85c6179ee2812c5bc5223b165d5da2a8ebf81330bf88658569237d434d719; record id: ctdnalit-20261011-zeng2026-result-pe-validation-methylation-auroc; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 275c41eb3cf4f7b413caa1a2607af1baac3098ee2a7d5482128b420c6b8c2ff2; record id: ctdnalit-20261011-zeng2026-result-pe-validation-methylation-sensitivity-99spec; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: c92739a146c77001b1bbd215c47ffa12d0ad3882a8b6309afa3e12eafbecba4f; record id: ctdnalit-20261011-zeng2026-result-pe-validation-nucleosome-peak-auroc; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 332b8615640951885dd6c8141fe06a98c33a8190adf2500e33c5b01119483ecf; record id: ctdnalit-20261011-zeng2026-result-pe-validation-nucleosome-peak-sensitivity-99spec; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 8462d8bb65e9a14da1185c676ea813318c25af2a2764b0bacc43172d459e6a9f; record id: ctdnalit-20261011-zeng2026-result-pe-validation-ratios-methylation-1pct-auroc; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: b4671462c901e061fd4ca4a06848601bd3373c91e63b4e2c70745e10d24e9819; record id: ctdnalit-20261011-zeng2026-result-pe-validation-ratios-methylation-1pct-sensitivity-99spec; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 04540e8f40c23a80ed516304f7961286403a52fd22fc1d6f70e4dc12ad6411d0; record id: ctdnalit-20261011-zeng2026-source-article; fields: status; attributes.artifact_sha256; sha256: 14e562e77825d183e70cbfb33efc8db055781fca389a81fbd03555aad9c9c003; record id: ctdnalit-20261011-zeng2026-source-source-data-fig4; fields: status; attributes.artifact_sha256; sha256: 53d9d739aa6fbe6c6021403a20027a73229eaf176892d4e2b0625e426ab83e8f; record id: use-case-plasma-ctdna-fragmentomics; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: 01d27c2ce64a391055bddc6dec9d5db208df9bee3d5e679045dd3f4f04a0ca08